<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110524</url>
  </required_header>
  <id_info>
    <org_study_id>TP1027</org_study_id>
    <nct_id>NCT02110524</nct_id>
  </id_info>
  <brief_title>CVI Drug Coated Balloon First In Human Trial</brief_title>
  <official_title>Prospective, Controlled, Multi-Center, Open, Single Arm Study for the Treatment of Subjects Presenting De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using a Paclitaxel-Coated Percutaneous Angioplasty Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectranetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and the inhibition of restenosis of the CVI
      Paclitaxel-coated PTA Balloon Catheter in the treatment of de-novo occluded/stenotic or
      reoccluded/restenotic superficial femoral (SFA) or popliteal arteries.

      The primary endpoint for this analysis is late lumen loss at six (6) months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, controlled, multi-center, open, single arm study

      Main cohort: 50; pre-specified treatment group: 30. Total patients: 80
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: Angiographic late lumen loss</measure>
    <time_frame>6Month</time_frame>
    <description>difference between minimum lumen diameter after intervention and follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoint: Major Adverse Event (MAE) rate</measure>
    <time_frame>6Months</time_frame>
    <description>composite rate of cardiovascular death, index limb amputation and ischemia driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>CVI Drug Coated Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty</intervention_name>
    <arm_group_label>CVI Drug Coated Balloon</arm_group_label>
    <other_name>CVI Paclitaxel-coated, Percutaneous Transluminal Angioplasty (PTA) Balloon</other_name>
    <other_name>Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with symptomatic leg ischemia, requiring treatment of SFA or popliteal (P1
             segment) artery

          -  De novo or restenotic lesion(s) &gt;70% within the SFA and popliteal arteries in a single
             limb which are ≥3 cm and ≤15 cm in cumulative total length (by visual estimation).

          -  Target vessel reference diameter ≥3 mm and ≤7 mm (by visual estimation).

          -  Rutherford classification of 2, 3 or 4

        Exclusion Criteria:

          -  Lesion length is &lt;3 cm or &gt;15 cm or there is no normal proximal arterial segment in
             which duplex ultrasound velocity ratios can be measured.

          -  Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries)
             with significant lesions (≥ 50% stenosis) may not be treated during the same
             procedure.

          -  Treatment of the contralateral limb during the same procedure or within 30 days of the
             study procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Schröder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish Hospital Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jewish Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

